Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162166817> ?p ?o ?g. }
- W2162166817 endingPage "148" @default.
- W2162166817 startingPage "139" @default.
- W2162166817 abstract "Two separate studies were conducted, the first to evaluate the maximal tolerated dose and the second the efficacy of raltitrexed plus oxaliplatin in conjunction with preoperative chemoradiation in patients with resectable T3 rectal carcinoma.A total of 48 patients received radiotherapy (50 Gy) administered to the posterior pelvis 5 d/wk for 5 weeks. Combination raltitrexed (3 mg/m(2)) and oxaliplatin (60 to 130 mg/m(2)) was administered on Days 1, 19, and 38.The recommended dose of oxaliplatin is 130 mg/m(2) (maximal tolerated dose not reached). No patients developed Grade 4 acute toxicity. Grade 3 acute toxicity occurred in 9 patients (18.7%). It was hematologic in 1 patient and GI in 1 patient; 7 patients had an asymptomatic increase of transaminase. Surgery was performed in 47 (98%) of 48 patients. Of the 47 patients, 42 underwent sphincter-saving surgery; in 19, the tumor at diagnosis was located <30 mm from the anorectal ring. Chemoradiation in combination with raltitrexed and oxaliplatin produced high rates of tumor response. The overall tumor downstaging rate was 73% for T and N stages. A complete pathologic tumor response (pT0) or microscopic tumor foci (pTmic) was observed in 28 patients. The tumor regression grade (TRG), using the Mandard scoring system, was TRG1 in 16 patients (43.2%), TRG2 in 12 (32.4%), TRG3 in 12 (32.4%), TRG4 in 6 (16.2%), and TRG5 in 1 patient (2.7%).Raltitrexed plus oxaliplatin combined with pelvic radiotherapy was effective and well tolerated in patients with resectable T3 rectal carcinoma." @default.
- W2162166817 created "2016-06-24" @default.
- W2162166817 creator A5000102814 @default.
- W2162166817 creator A5000176548 @default.
- W2162166817 creator A5006142970 @default.
- W2162166817 creator A5008208200 @default.
- W2162166817 creator A5013039096 @default.
- W2162166817 creator A5026203664 @default.
- W2162166817 creator A5036483390 @default.
- W2162166817 creator A5037221378 @default.
- W2162166817 creator A5038579623 @default.
- W2162166817 creator A5038926782 @default.
- W2162166817 creator A5077596666 @default.
- W2162166817 creator A5090026814 @default.
- W2162166817 date "2004-09-01" @default.
- W2162166817 modified "2023-10-18" @default.
- W2162166817 title "Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies" @default.
- W2162166817 cites W1919629952 @default.
- W2162166817 cites W1963782590 @default.
- W2162166817 cites W1974720222 @default.
- W2162166817 cites W1977468182 @default.
- W2162166817 cites W2005750330 @default.
- W2162166817 cites W2009070471 @default.
- W2162166817 cites W2010880317 @default.
- W2162166817 cites W2018216673 @default.
- W2162166817 cites W2022848495 @default.
- W2162166817 cites W2026097725 @default.
- W2162166817 cites W2033465919 @default.
- W2162166817 cites W2047718148 @default.
- W2162166817 cites W2051183975 @default.
- W2162166817 cites W2054240496 @default.
- W2162166817 cites W2061193866 @default.
- W2162166817 cites W2063655425 @default.
- W2162166817 cites W2091307715 @default.
- W2162166817 cites W2102966659 @default.
- W2162166817 cites W2109868752 @default.
- W2162166817 cites W2140081776 @default.
- W2162166817 cites W2147271502 @default.
- W2162166817 cites W2149356308 @default.
- W2162166817 cites W2150459940 @default.
- W2162166817 cites W2150983705 @default.
- W2162166817 cites W2167805334 @default.
- W2162166817 cites W2183500698 @default.
- W2162166817 cites W2203850004 @default.
- W2162166817 cites W2230940273 @default.
- W2162166817 cites W2323577539 @default.
- W2162166817 cites W2324695046 @default.
- W2162166817 doi "https://doi.org/10.1016/j.ijrobp.2004.01.051" @default.
- W2162166817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15337549" @default.
- W2162166817 hasPublicationYear "2004" @default.
- W2162166817 type Work @default.
- W2162166817 sameAs 2162166817 @default.
- W2162166817 citedByCount "54" @default.
- W2162166817 countsByYear W21621668172012 @default.
- W2162166817 countsByYear W21621668172013 @default.
- W2162166817 countsByYear W21621668172015 @default.
- W2162166817 countsByYear W21621668172017 @default.
- W2162166817 countsByYear W21621668172018 @default.
- W2162166817 countsByYear W21621668172019 @default.
- W2162166817 countsByYear W21621668172020 @default.
- W2162166817 countsByYear W21621668172021 @default.
- W2162166817 countsByYear W21621668172022 @default.
- W2162166817 crossrefType "journal-article" @default.
- W2162166817 hasAuthorship W2162166817A5000102814 @default.
- W2162166817 hasAuthorship W2162166817A5000176548 @default.
- W2162166817 hasAuthorship W2162166817A5006142970 @default.
- W2162166817 hasAuthorship W2162166817A5008208200 @default.
- W2162166817 hasAuthorship W2162166817A5013039096 @default.
- W2162166817 hasAuthorship W2162166817A5026203664 @default.
- W2162166817 hasAuthorship W2162166817A5036483390 @default.
- W2162166817 hasAuthorship W2162166817A5037221378 @default.
- W2162166817 hasAuthorship W2162166817A5038579623 @default.
- W2162166817 hasAuthorship W2162166817A5038926782 @default.
- W2162166817 hasAuthorship W2162166817A5077596666 @default.
- W2162166817 hasAuthorship W2162166817A5090026814 @default.
- W2162166817 hasConcept C121608353 @default.
- W2162166817 hasConcept C126322002 @default.
- W2162166817 hasConcept C141071460 @default.
- W2162166817 hasConcept C2776694085 @default.
- W2162166817 hasConcept C2779268555 @default.
- W2162166817 hasConcept C2780962732 @default.
- W2162166817 hasConcept C2781074409 @default.
- W2162166817 hasConcept C509974204 @default.
- W2162166817 hasConcept C526805850 @default.
- W2162166817 hasConcept C71924100 @default.
- W2162166817 hasConcept C90924648 @default.
- W2162166817 hasConceptScore W2162166817C121608353 @default.
- W2162166817 hasConceptScore W2162166817C126322002 @default.
- W2162166817 hasConceptScore W2162166817C141071460 @default.
- W2162166817 hasConceptScore W2162166817C2776694085 @default.
- W2162166817 hasConceptScore W2162166817C2779268555 @default.
- W2162166817 hasConceptScore W2162166817C2780962732 @default.
- W2162166817 hasConceptScore W2162166817C2781074409 @default.
- W2162166817 hasConceptScore W2162166817C509974204 @default.
- W2162166817 hasConceptScore W2162166817C526805850 @default.
- W2162166817 hasConceptScore W2162166817C71924100 @default.
- W2162166817 hasConceptScore W2162166817C90924648 @default.
- W2162166817 hasIssue "1" @default.